ABSTRACT
Objective:To analyse the curative effect and immune indices of tripterygium glycosides on glomerulonephritis rats . Methods:Aged Wistar rats were randomly divided into 3 groups , Group A:glomerulonephritis model rats received tripterygium glyco-sides treatment;Group B:healthy Wistar rats received no treatment; Group C: glomerulonephritis model rats received no treatment . Results:12 weeks after experiment , Group A and Group C had higher levels of 24-hour urine protein than Group B and these of pre-experiment(P<0.05).Group A had a lower level of 24-hour urine protein than Group C(P<0.05).Group A and Group C had high-er levels of TG, TC than Group B, with lower levels of ALB than Group B (P<0.05).Group A had lower levels of TG, TC than Group C, but a higher level of ALB than Group C (P<0.05).Group A had a higher rate of 0-1 grades in pathology grade than group C(χ2 =6.667,P=0.010).Group C had higher levels of TNF-αand IL-6 than Group B and Group A (P<0.05).Conclusion:Tripterygium glycosides can reduce the urine protein excretion of rats that with mesangial proliferative glomerulonephritis , rectify dyslip-idosis, raise plasma-albumin, decrease the protein expression of TNF-αand IL-6 in glomerulus.
ABSTRACT
Objective To explore the relationship between plasma interleukin-11(sIL-11) level and platelet count post-chemotherapy with hematological malignancy patients and analyse a sIL-11 level which may maintain a safe platelet count so as to guide the treatment. Methods Blood samples were collected from the patients with hematological malignancy at certain time point of pre-and post-chemotherapy, and serum level of sIL-11 and platelet count were determined separately. Different statistical methods were applied to test the relationship between sIL-11 level and platelet changes. Results 99 cases finished this study. The findings are: the sIL-11 level went up and reached the peak on day 6 post-chemotherapy, while the platelet count kept dropping to the lowest on day 10, the sIL-11 peak occurred before the lowest platelet count, patients with faster sIL-11 increase may maintain a comparatively higher plateled count. 99 eases were grouped according to the lowest platelet count and compared: the group with higher platelet count tend to have higher peak sIL-11, more cases with higher peak sIL-11, with faster daily average sIL-11 increase, the lowest platelet count occurred later. Logistic regression analysis showed the factors contributed to lower platelet includes slower daily average sIL-11 increase and sIL-11 level less than 2000 pg/ml on Day4 post-chemotherapy. Conclusion There were correlation between the serum sIL-11 level and platelet counts, the platelet count change may be predicted by determining the plasma sIL-11 level post-chemotherapy. Patients with sIL-11 level less than 2000 pg/ml on Day4 post-chemotherapy may be endangered with severe thrombocytopenia, rhIL-11 or platelet transfusion treatment should be considered.